Bayer acquires rights to develop and commercialize ISIS-FXI Rx to prevent thrombosis

WASHINGTON - May 5, 2015 - PRLog -- Isis Pharmaceuticals has entered into an agreement with Bayer Healthcare to commercialize and develop ISIS-FXIRx for the prevention of thrombosis. In accordance with the terms, Isis will receive a $100 million upfront payment plus $55 million contingent on the advancement of the clinical development program following a Phase 2 study. Isis is also set to receive additional commercial milestone payments plus tiered royalties in the low to high twenty percent range on gross margins of ISIS-FXIRx. Bayer will be responsible for the global clinical development, regulatory and commercialization of the treatment. Bayer plans to assess the treatment’s therapeutic profile in patients that cannot utilize anticoagulants, for instance, patients at high risk high risk of bleeding due to multiple co-morbidities.

"We believe Bayer, a leading pharmaceutical company in the treatment of thrombotic disease, is the ideal partner for ISIS-FXIRx. This transaction further demonstrates Bayer's commitment to the field. Bayer has the expertise, commitment and resources to develop ISIS-FXIRx in areas where unmet medical needs exist. We are pleased with the value of this partnership, which supports a robust development program to maximize the value of ISIS-FXIRx globally and which allows us to participate significantly in future commercial success," saidStanley Crooke, Ph.D, M.D., chief executive officer at Isis Pharmaceuticals.  "We believe that this transaction represents the right deal, with the right partner and the right development plan."

CANDIDATES WHO WANT TO BREAK INTO PHARMACEUTICAL SALES!

With such industry leaders paving the way on identifying new beneficial therapeutic breakthroughs, they will need both certified and qualified individuals to promote their diversified product portfolio. When industry leaders look for new candidates for sales/marketing positions, they look toward individuals that are industry trained. Companies are looking for people that have the background to promote their product both proficiently and efficiently.

The NAPSRx® is a trade association for pharmaceutical sales reps, sales managers and sales trainers who work in the pharmaceutical industry. NAPSRx® provides Continuing Medical Education to its members as well as CNPR® Certification to candidates who look to enter a pharmaceutical sales career. The CNPR® Program represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Upon successful completion of the training each student will receive the Certification Mark of the CNPR®.

Individuals that are interested in becoming a Certified National Pharmaceutical Representative (CNPR) can contact the National Association of Pharmaceutical Sales Representatives(NAPSRx) for more information or visit the website at http://napsronline.org/.